The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer

Volumn 100, Issue , 2016, Pages 63-70

  Jiang, Tao ^a   Zhai, Changyun ^b   Su, Chunxia ^a   Ren, Shengxiang ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Circulating cell free DNA; Diagnosis; Meta analysis; Non small cell lung cancer

Indexed keywords

BETA ACTIN; CIRCULATING CELL FREE DNA; DNA; TUMOR MARKER; UNCLASSIFIED DRUG; ACTIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; COCHRANE LIBRARY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA ISOLATION; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; WEB OF SCIENCE; ADULT; AGED; EARLY CANCER DIAGNOSIS; FEMALE; GENETICS; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ACTINS; ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84983000163     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.013     Document Type: Article

References (34)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics. CA. Cancer J. Clin. 65 (2015), 87–108 (2012).
2. [2] Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., Wong, K.K., Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14 (2014), 535–546.
3. [3] Wood, S.L., Pernemalm, M., PA Crosbie and AD Whetton molecular histology of lung cancer: from targets to treatments. Cancer Treat. Rev. 41 (2015), 361–375.
4. [4] Tsao, A.S., Scagliotti, G.V., Bunn, P.A. Jr., Carbone, D.P., Warren, G.W., Bai, C., et al. Scientific advances in lung cancer. J. Thorac. Oncol., 2015 (2016).
5. [5] Spira, A., Halmos, B., Powell, C.A., Update in Lung Cancer 2014. Am. J. Respir. Crit. Care Med. 192 (2015), 283–294.
6. [6] Padda, S.K., Burt, B.M., Trakul, N., Wakelee, H.A., Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin. Oncol. 41 (2014), 40–56.
7. [7] Patz, E.F. Jr., Rossi, S., Harpole, D.H. Jr., Herndon, J.E., Goodman, P.C., Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 117 (2000), 1568–1571.
8. [8] Zhang, R., Shao, F., Wu, X., Ying, K., Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 69 (2010), 225–231.
9. [9] Chen, X., Zhou, F., Li, X., Yang, G., Zhang, L., Ren, S., et al. Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer. J. Thorac. Oncol. 10 (2015), 1163–1171.
10. [10] Jiang, T., Ren, S., Zhou, C., Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer 90 (2015), 128–134.
11. [11] Szpechcinski, A., Chorostowska-Wynimko, J., Struniawski, R., Kupis, W., Rudzinski, P., Langfort, R., et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br. J. Cancer 113 (2015), 476–483.
12. [12] Sozzi, G., Conte, D., Leon, M., Ciricione, R., Roz, L., Ratcliffe, C., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 21 (2003), 3902–3908.
13. [13] Ulivi, P., Mercatali, L., Zoli, W., Dell'amore, D., Poletti, V., Casoni, G.L., et al. Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. Thorax 63 (2008), 843–844.
14. [14] Ulivi, P., Mercatali, L., Casoni, G.L., Scarpi, E., Bucchi, L., Silvestrini, R., et al. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One, 8, 2013, e57401.
15. [15] Chiappetta, C., Anile, M., Leopizzi, M., Venuta, F., Della Rocca, C., Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer. Clin. Chim. Acta 425 (2013), 93–96.
16. [16] Herrera, L.J., Raja, S., Gooding, W.E., El-Hefnawy, T., Kelly, L., Luketich, J.D., et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin. Chem. 51 (2005), 113–118.
17. [17] van der Drift, M.A., Hol, B.E., Klaassen, C.H., Prinsen, C.F., van Aarssen, Y.A., Donders, R., et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68 (2010), 283–287.
18. [18] Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151 (2009), W65–94.
19. [19] Whiting, P.F., Rutjes, A.W., Westwood, M.E., Mallett, S., Deeks, J.J., Reitsma, J.B., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155 (2011), 529–536.
20. [20] Deeks, J.J., Macaskill, P., Irwig, L., The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J. Clin. Epidemiol. 58 (2005), 882–893.
21. [21] Kumar, S., Guleria, R., Singh, V., Bharti, A.C., Mohan, A., Das, B.C., Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 70 (2010), 211–217.
22. [22] Yoon, K.A., Park, S., Lee, S.H., Kim, J.H., Lee, J.S., Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J. Mol. Diagn. 11 (2009), 182–185.
23. [23] Szpechcinski, A., Dancewicz, M., Kopinski, P., Kowalewski, J., Chorostowska-Wynimko, J., Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls. Eur. J. Med. Res. 14:Suppl. 4 (2009), 237–240.
24. [24] Paci, M., Maramotti, S., Bellesia, E., Formisano, D., Albertazzi, L., Ricchetti, T., et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64 (2009), 92–97.
25. [25] Ludovini, V., Pistola, L., Gregorc, V., Floriani, I., Rulli, E., Piattoni, S., et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J. Thorac. Oncol. 3 (2008), 365–373.
26. [26] Xie, G.S., Hou, A.R., Li, L.Y., Gao, Y.N., Cheng, S.J., Quantification of plasma DNA as a screening tool for lung cancer. Chin. Med. J. (Engl.) 117 (2004), 1485–1488.
27. [27] Sozzi, G., Conte, D., Mariani, L., Lo Vullo, S., Roz, L., Lombardo, C., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61 (2001), 4675–4678.
28. [28] Catarino, R., Coelho, A., Araujo, A., Gomes, M., Nogueira, A., Lopes, C., et al. Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One, 7, 2012, e38559.
29. [29] Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32 (2014), 579–586.
30. [30] Diehl, F., Schmidt, K., Choti, M.A., Romans, K., Goodman, S., Li, M., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14 (2008), 985–990.
31. [31] Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med., 6, 2014, 224ra24.
32. [32] Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 16368–16373.
33. [33] Beaver, J.A., Jelovac, D., Balukrishna, S., Cochran, R.L., Croessmann, S., Zabransky, D.J., et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 20 (2014), 2643–2650.
34. [34] Kinugasa, H., Nouso, K., Miyahara, K., Morimoto, Y., Dohi, C., Tsutsumi, K., et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer, 2015 (Epub ahead of print).